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BACKGROUND AND PURPOSE
Oxaliplatin is a platinum-based chemotherapeutic drug used as a ﬁrst-line therapy for colorectal cancer. However, its use is as-
sociated with severe gastrointestinal side-effects resulting in dose limitations and/or cessation of treatment. In this study, we
tested whether oxidative stress, caused by chronic oxaliplatin treatment, induces enteric neuronal damage and colonic
dysmotility.
EXPERIMENTAL APPROACH
Oxaliplatin (3 mg·kg1 per day) was administered in vivo to Balb/c mice intraperitoneally three times a week. The distal colon was
collected at day 14 of treatment. Immunohistochemistry was performed in wholemount preparations of submucosal and
myenteric ganglia. Neuromuscular transmission was studied by intracellular electrophysiology. Circular muscle tone was studied
by force transducers. Colon propulsive activity studied in organ bath experiments and faeces were collected to measure water
content.
KEY RESULTS
Chronic in vivo oxaliplatin treatment resulted in increased formation of reactive oxygen species (O2ˉ), nitration of proteins,
mitochondrial membrane depolarisation resulting in the release of cytochrome c, loss of neurons, increased inducible NOS
expression and apoptosis in both the submucosal and myenteric plexuses of the colon. Oxaliplatin treatment enhanced NO-
mediated inhibitory junction potentials and altered the response of circular muscles to the NO donor, sodium nitroprusside. It also
reduced the frequency of colonic migrating motor complexes and decreased circular muscle tone, effects reversed by the NO
synthase inhibitor, Nω-Nitro-L-arginine.
CONCLUSION AND IMPLICATIONS
Our study is the ﬁrst to provide evidence that oxidative stress is a key player in enteric neuropathy and colonic dysmotility leading
to symptoms of chronic constipation observed in oxaliplatin-treated mice.
Abbreviations
CMMC, colonic migrating motor complex; EJPs, excitatory junction potentials; ENS, enteric nervous system; fIJPs, fast
inhibitory junction potentials; iNOS, inducible NOS; IR, immunoreactive; L-NNA, Nω-nitro-L-arginine; nNOS, neuronal
NOS; sIJPs, slow inhibitory junction potentials; SNP, sodium nitroprusside
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Introduction
Oxaliplatin, usually administered together with 5-ﬂuo-
rouracil and leucovorin, is a third generation platinum-based
agent used as the ﬁrst line of treatment for tumours resistant
to the ﬁrst and second generation platinum-based agents, cis-
platin and carboplatin (Raymond et al., 1998). Combinations
containing oxaliplatin have shown great therapeutic poten-
tial, improving progression-free and overall survival rates of
patients with colorectal cancer (André et al., 2004; De
Gramont et al., 2007).
Oxaliplatin exerts its cytotoxic effects via formation of
platinum-DNA adducts that trigger immobilization of themi-
totic cell cycle and stimulate apoptosis of dividing cells (Gra-
ham et al., 2000; Goodisman et al., 2006). At clinically
recommended doses, oxaliplatin is reported to be less toxic
for the auditory, haematological and renal systems than cis-
platin and carboplatin (Raymond et al., 1998). However,
oxaliplatin-induced neurotoxicity differs from that induced
by other platinum compounds, triggering both acute and de-
layed peripheral neuropathies as well as gastrointestinal dys-
functions (Stojanovska et al., 2015).
Gastrointestinal side-effects are a predominant cause of
dose limitation, presenting a constant challenge for efﬁcient
and tolerable treatment of cancer (Verstappen et al., 2003;
McQuade et al., 2014). About 40% of patients receiving stan-
dard dose chemotherapy and nearly all patients receiving
high dose chemotherapy exhibit pain, ulceration, bloating,
vomiting, diarrhoea and/or constipation throughout the
course of treatment (McQuade et al., 2014). Platinum-based
agents speciﬁcally are linked to a heightened incidence of
gastrointestinal side-effects with up to 90% of patients
experiencing vomiting, nausea and/or diarrhoea during
the course of treatment (Sharma et al., 2005). Addition of
platinum-based chemotherapeutics to combination regimes
(such as FOLFOX – a combination of 5-ﬂuorouracil,
leucovorin and oxaliplatin) increases the incidence of
chronic diarrhoea and treatment-related death (Souglakos
et al., 2006). Gastrointestinal side-effects can persist up to
10 years after the treatment has ceased (Denlinger and
Barsevick, 2009).
Gastrointestinal functions are controlled by the enteric
nervous system (ENS) embedded in the wall of the
gastrointestinal tract (Furness, 2012). Damage to the ENS un-
derlies gastrointestinal dysfunction inmany pathophysiolog-
ical conditions (Furness, 2012). To date, few studies have
investigated the effects of platinum-based chemotherapeu-
tics on enteric neurons in animal models (Vera et al., 2011;
Wafai et al., 2013; Pini et al., 2016). These studies reported
signiﬁcant reductions in the number of myenteric neurons
in the colon and stomach, alongside altered expression of
neuronal NOS (nNOS) following in vivo treatment with cis-
platin (Vera et al., 2011; Pini et al., 2016) and oxaliplatin
(Wafai et al., 2013). These changes in the ENS are correlated
with reductions in gastrointestinal transit and colonic pro-
pulsive activity in oxaliplatin-treated animals, which may
be related to symptoms of constipation or diarrhoea.
NO, synthesizedby the NOS enzymes, is a highly reactive
and widely distributed transmitter found throughout both
the central and peripheral nervous systems. In the gastroin-
testinal tract, NO is a well-established mediator of vasodila-
tion and gastrointestinal relaxation (Takahashi, 2003;
Bornstein et al., 2004). Two types of NOS participate in nor-
mal physiological responses, nNOS localized to neurons and
endothelial NOS (eNOS) localized to the endothelium. In-
creased expression of inducible NOS (iNOS) occurs during
times of cellular stress. Neurons containing nNOS are the pri-
mary source of NO in the ENS and represent approximately
30% of the neuronal population in the myenteric plexus of
the mouse small intestine and colon (Qu et al., 2008; Wafai
et al., 2013). In enteric ganglia, nNOS is expressed by de-
scending interneurons and by inhibitory motor neurons sup-
plying the intestinal smooth muscle (Lecci et al., 2002).
Moreover, a myogenic nNOS isoform is expressed by
gastrointestinal smooth muscle cells (Daniel et al., 2000).
NO released from both neurons and smooth muscle is essen-
tial for sphincter relaxation and generation of complex
gastrointestinal motor patterns, which contribute to propul-
sion during digestion (Sarna et al., 1993; Roberts et al., 2007;
Roberts et al., 2008). Altered expression of nNOS in the ENS
has been linked to several pathological conditions, and
increased levels of nNOS in the ENS can be indicative of oxi-
dative stress (Rivera et al., 2011a). The effects of oxidative
stress on post mitotic cells, including enteric neurons, can
be cumulative, resulting in neuronal loss and deterioration
of neuronal function impairing gastrointestinal motility
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patterns (Chandrasekharan et al., 2011). The role of oxidative
stress in chemotherapy-induced gastrointestinal dysfunction
has not been explored. This study investigated the role of ox-
idative stress in enteric neuronal damage and colonic
dysmotility caused by in vivo oxaliplatin treatment.
Methods
Animals
All animal care and experimental procedures were approved
by the Victoria University Animal Experimentation Ethics
Committee and performed in accordance with the guidelines
of the National Health and Medical Research Council
Australian Code of Practice for the Care and Use of Animals
for Scientiﬁc Purposes. Animal studies are reported in compli-
ance with the ARRIVE guidelines (Kilkenny et al., 2010;
McGrath and Lilley, 2015).
Male Balb/c mice aged 6–8 weeks (18–25 g) supplied from
the Animal Resources Centre (Perth, Australia) were used for
all experiments. Mice had free access to food and water and
were kept under a 12 h light/dark cycle in a well-ventilated
room at an approximate temperature of 22°C. Mice acclima-
tized for a minimum of 5 days and amaximum of 7 days prior
to the commencement of in vivo intraperitoneal injections. A
total of 70 mice were used for this study.
In vivo oxaliplatin injections
Mice were randomly assigned into two groups: oxaliplatin-
treated and sham-treated. Mice received intraperitoneal in-
jections of oxaliplatin (Tocris Bioscience, UK), 3 mg·kg1
per dose, 3 times a week via a 26 gauge needle. Oxaliplatin
was dissolved in sterile water in order to make 102 M·L1
stock solutions and refrigerated at 20°C. The stock was then
defrosted and further diluted with sterile water to make
103 M·L1 solutions for injections. The oxaliplatin dose
was calculated to be equivalent to standard human dose per
body surface area (Renn et al., 2011). Sham-treated mice re-
ceived sterile water via intraperitoneal injection 3 times a
week via a 26 gauge needle. The volume injected did not ex-
ceed 200 μL per injection. Mice were killed via cervical dislo-
cation 14 days after the ﬁrst injection. Colons were collected
for in vitro experiments.
Assessment of mitochondrial superoxide
production
MitoSOX™ Red M36008 (Invitrogen, Australia) was used to
visualize mitochondrially-derived superoxide in whole-
mount preparations of submucosal and myenteric ganglia of
the distal colon. Freshly excised distal colon preparations
were dissected to expose submucosal and myenteric ganglia.
Preparations were incubated in oxygenated physiological sa-
line with MitoSOX™ Red M36008 (5 μM) in a gently shaking
incubator Unimax 1010 (Heidolph Instruments, Germany)
at a constant temperature of 37°C for 40 min. Tissues were
washed (2 × 30 min) with oxygenated physiological saline
(composition in mM: NaCl 118, KCl 4.6, CaCl2 3.5, MgSO4
1.2, NaH2PO4 1, NaHCO3 25 and d-Glucose 11; bubbled with
95%O2 and 5%CO2) and ﬁxed in 4% paraformaldehyde over-
night at 4°C. The following day tissues were washed
(2 × 30 min) with physiological saline and mounted on glass
slides with DAKO ﬂuorescentmountingmedium for imaging.
All images were captured at identical acquisition exposure-
time conditions, calibrated to standardized minimum base-
line ﬂuorescence, converted to binary and changes in ﬂuores-
cence from baseline were measured in arbitrary units (arb.
units) using Image J software (NIH, MD, USA). The corrected
total ﬂuorescence was calculated as previously described (Bur-
gess et al., 2010) in 32 5 × 5 μm2 boxes within myenteric gan-
glia from each preparation to exclude ﬂuorescence outside
the ganglia.
Mitochondrial membrane potential assay
Mitochondrial membrane potential changes in cells may
be detected with the cationic, lipophilic JC-10 dye. In
normal cells, JC-10 concentrates in the mitochondrial
matrix where it forms red ﬂuorescent aggregates (JC aggre-
gates). In contrast, apoptotic cells stain in green ﬂuorescent
colour (JC monomeric form) due to the JC-10-labelled release
of cytochrome c diffusing out of the mitochondria as a result
of mitochondrial depolarisation and increased permeability.
JC-10 ﬂuorescent mitochondrial membrane potential
microplate assay kit (Abcam, MA, USA) was used to detect mi-
tochondrial membrane potential changes, and the release of
cytochrome c from damaged mitochondria in the myenteric
ganglia of the distal colon. Freshly excised distal colon
preparations from sham and oxaliplatin-treated mice were
bathed in oxygenated physiological saline and dissected to
expose the myenteric ganglia. Immediately following dissec-
tion, preparations were incubated for 20 min with 500 μL of
JC-10 dye solution (buffer A) in a gently shaking incubator
Unimax 1010 (Heidolph Instruments, Germany) at a
constant temperature of 37°C. After 20 min, 500 μL of buffer
B solution was added to tissue preparations and allowed to in-
cubate for another 20 min in a gently shaking incubator at a
constant temperature of 37°C. Immediately following ﬁnal
incubation, tissues were mounted on glass slides with DAKO
ﬂuorescent mounting medium for imaging under a Nikon
Eclipse Ti laser scanning microscope (Nikon, Japan).
Immunohistochemistry
Collected tissues (distal and proximal colon) were placed in
oxygenated PBS (pH 7.2) containing nicardipine (3 μM)
(Sigma-Aldrich, Australia) for 20 min to inhibit smooth mus-
cle contraction. Samples were cut open along the mesenteric
border, cleared of their contents, maximally stretched and
dissected mucosa down to expose either the submucosal
plexus (distal colon) or myenteric plexus (distal and
proximal colon). Tissues were then ﬁxed with Zamboni’s ﬁx-
ative (2% formaldehyde, 0.2% picric acid) overnight at 4°C.
Preparations were cleared of ﬁxative by washing three times
for 10 min with DMSO (Sigma-Aldrich, Australia) followed
by 3 × 10 min washes with PBS. Fixed tissues were stored at
4°C in PBS for a maximum of 5 days.
Whole-mount preparations were incubated with 10%
normal donkey serum (Chemicon, USA) for 1 h at room tem-
perature. Tissues were then washed (2 × 5 min) with PBS and
incubated with primary antibodies against β-tubulin class III
(TuJ1) (chicken, 1:1000, Abcam, MA, USA), nitrotyrosine
(rabbit, 1:1000, Millipore, CA, USA), nNOS (goat, 1:500,
Abcam, MA, USA) and cleaved caspase-3 (rabbit, 1:500, Cell
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Signalling Technologies, MA, USA) overnight at 4°C. Tissues
were then washed in PBS (3 × 10 min) before incubation with
species-speciﬁc secondary antibodies labelled with different
ﬂuorophores: donkey anti-chicken Alexa 594 (1:200, Jackson
Immuno research Laboratories, PA, USA), donkey anti-goat
Alexa 488 (1:200, Jackson Immuno research Laboratories,
PA, USA) and donkey anti-rabbit Alexa 488 and 647 (1:200,
Jackson Immuno research Laboratories, PA, USA) for 2 h at
room temperature. Double immunohistochemical labelling
was performed using mixtures of antibodies raised in differ-
ent species and using species speciﬁc secondary antibodies
labelled with different ﬂuorophores. Tissues were given a
further 3 × 10 min washes with PBS, followed by a 2 min
incubation with the ﬂuorescent nucleic acid stain, 4′-6-
diamidino-2-phenylindole (DAPI; 14 nM) (Invitrogen,
Australia). Whole-mount preparations were given three ﬁnal
10 min washes in PBS and thenmounted on glass slides using
ﬂuorescent mounting medium (DAKO, Australia). Whole-
mount preparations were observed under a Nikon Eclipse Ti
laser scanning microscope (Nikon, Japan); eight randomly
chosen images from each preparation were captured with a
20× objective and processed using NIS Elements software
(Nikon, Japan). The numbers of β-tubulin-immunoreactive
(IR) neurons, nNOS-IR neurons and neurons displaying
translocation of nitrated proteins to the nuclei were quanti-
ﬁed in both submucosal and myenteric ganglia within a
2 mm2 area of each distal colon preparation. Proximal colon
preparations were use to quantify the numbers of β-tubulin-
IR and nNOS-IR neurons. Images were then calibrated to
standardized minimum baseline ﬂuorescence, converted to
binary, and changes in caspase-3 ﬂuorescence were detected
using Image J software (NIH, MD, USA). Quantitative analy-
ses were conducted blindly.
Histology
The distal colon was harvested and placed in a 10% formalin
solution overnight and then transferred into 70% ethanol the
following day. Parafﬁn embedded colon sections were cut
5 μm thick and de-waxed in a 60°C oven for 30 min. To
examine the morphological changes to the colon, a
standard haematoxylin and eosin staining protocol was
followed (26, 27). Ten sections per preparation were
analysed. All images were analysed blindly.
Imaging
Three dimensional (z-series) images of wholemount prepara-
tions were taken using a Nikon Eclipse Ti laser scanning mi-
croscope (Nikon, Japan. Fluorophores were visualized using
excitation ﬁlters for Alexa 594 Red (excitation wavelength
559 nm), Alexa 488 (excitation wavelength 473 nm) and
Alexa 405 (excitation wavelength 405 nm). Z-series images
were taken at step size of 1.75 μm (1600 × 1200 pixels).
Western blotting
The whole colon was harvested, cut along themesenteric bor-
der and pinned mucosa side up to a silicone-based petri dish
containing physiological saline. The colon was ﬂushed of its
contents, and the mucosa, submucosa and the circular mus-
cle layers were dissected and discarded. The remaining longi-
tudinal muscle-myenteric plexus (LMMP) whole-mount
preparations were then snap frozen using liquid nitrogen.
Frozen tissues were homogenized with a Polytron
homogeniser (Kinematica AG, Lucerne, Switzerland) for 20 s
in ice-cold WB buffer (40 mM Tris, pH 7.5; 1 mM EDTA;
5 mM EGTA; 0.5% Triton X-100; 25 mM β-glycerophosphate;
25 mM NaF; 1 mM Na3VO4; 10 μg·mL1 leupeptin; and
1 mM PMSF), and the whole homogenate was used for West-
ern blot analysis. Sample protein concentrations were deter-
mined with a DC protein assay kit (Bio-Rad Laboratories,
Hercules, CA, USA), and equivalent amounts of protein from
each sample were dissolved in Laemmli buffer and subjected
to electrophoretic separation on SDS-PAGE acrylamide gels.
Following electrophoretic separation, proteins were trans-
ferred to a PVDF membrane, blocked with 5% powdered milk
in Tris-buffered saline containing 0.1% Tween 20 (TBST) for
1 h followed by an overnight incubation at 4°C with rabbit
anti-iNOS primary antibody (D6B6S, Cell Signalling Technol-
ogy, Danvers, MA, USA) dissolved in TBST containing 1%
BSA. The following day membranes were washed for 30 min
in TBST and then probed with a peroxidase-conjugated anti-
rabbit secondary antibody (Vector Laboratories, Burlingame,
CA, USA) for 1 h at room temperature. Following 30 min of
washing in TBST, the blots were developed with a DARQ
CCD camera mounted to a Fusion FX imaging system (Vilber
Lourmat, Germany) using ECL Prime reagent (Amersham,
Piscataway, NJ, USA). Densitometric measurements of the
protein of interest were carried out using Fusion CAPT Ad-
vance software (Vilber Lourmat, Germany). Membranes were
then stained with Coomassie Blue, scanned and total protein
loaded quantiﬁed using Image J software. The signal intensity
of the protein of interest was normalized to the signal for to-
tal protein loaded.
Intracellular recordings
Segments of the distal colon proximal to the pelvic brim were
collected from day 14 sham and oxaliplatin-treated mice and
placed in physiological saline bubbled with 95% O2 and 5%
CO2 at room temperature. The physiological saline contained
the L-type Ca2 channel blocker nicardipine (3 μM) (Sigma-
Aldrich, Australia) to limit contractions. The distal colon
was opened along the mesenteric border and pinned in a
Sylgard-lined (Dow Corning, USA) Petri dish. The mucosa
and submucosa were removed revealing the circular muscle
layer. A 20 mm long, full circumference segment was trans-
ferred into a Sylgard-lined recording chamber and pinned
with 50 μm gold-plated tungsten pins. The recording cham-
ber was placed on the stage of an inverted microscope ﬁtted
with ﬂuorescent optics (Zeiss Axiovert 200), and was contin-
uously superfused with physiological saline (3 mL·min1)
pre-heated to yield a bath temperature of 35°C. Following
2 h recovery from dissection (Carbone et al., 2012), circular
smooth muscle cells were impaled with conventional intra-
cellular borosilicate glass capillary electrodes ﬁlled with 5%
5,6-carboxyﬂuorescein in 20 mM Tris buffer (pH 7.0) in 1 M
KCl. Electrode resistances ranged from 60–120 MΩ. Record-
ings were made using an Axoclamp 2B ampliﬁer (Axon In-
struments, USA), digitised at 1–10 kHz via a Digidata 1440A
interface (Molecular Devices, USA) and stored using PClamp
10.0 (Molecular Devices) on a PC. Carboxyﬂuorescein-
labelled cells were identiﬁed as circular muscle cells in situ
from their morphology (Carbone et al., 2012). Intracellular
hyperpolarising current pulses (duration 500 ms, intensity
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100–500 pA) were used to determine input resistance (Rin). A
tungsten electrode (10–50 mm tip diameter, placed 1 mm cir-
cumferential to the recording microelectrode) was connected
to an ISO-Flex stimulator controlled by a Master-8 pulse gen-
erator (AMPI, Israel). Single pulse stimuli (20 V, 0.4 ms dura-
tion) and short trains of high frequency pulses (20 V, 3
pulses, 40 ms interval, 0.4 ms duration) were used to activate
nerve ﬁbres. Junction potential responses were recorded in
the impaled smooth muscle cells. Responses in 3–4 cells were
averaged per test condition, in each animal. Data were
analysed using AxoGraph 10 software.
Contraction force
Freshly excised distal colon was cut into 3 mm rings, cleaned
of connective tissue and fat and then placed in a custom built
organ-bath chamber containing physiological saline oxygen-
ated with 95% O2 and 5% CO2 and maintained at a constant
temperature of 37°C and pH of 7.4. Colonic rings were
mounted between two small metal hooks attached to force
displacement transducers (Zultek Engineering, Australia),
and stretched to a resting tension of 0.2 g. After 30 min, rings
were returned to resting tension and allowed to stabilize for
2 h with physiological saline changed every 20 min
(Habiyakare et al., 2014). Following stabilization, 10 μM so-
dium nitroprusside (SNP) was added to organ bath. Baseline
values were obtained by averaging 60 s of data 5 min prior
to drug application; maximum relaxation was calculated as
absolute change from the baseline values.
Colonic motility experiments
The entire colon was removed from day 14 sham and
oxaliplatin-treated mice and set up in organ-bath chambers
to record motor patterns in vitro (Wafai et al., 2013). Brieﬂy,
the colon was placed into warmed (35°C), oxygenated physi-
ological saline until the faecal pellets were expelled. The
empty colon was cannulated at both ends and arranged hori-
zontally in organ-bath chambers. The proximal end of the co-
lon was connected to a reservoir containing oxygenated
physiological saline to maintain intraluminal pressure. The
distal end was attached to an outﬂow tube that provided a
maximum of 2 cm H2O back-pressure. Organ baths were con-
tinuously superfused with oxygenated physiological saline
solution, and preparations were left to equilibrate for
30 min. Contractile activity of each segment was recorded
with a Logitech Quickcam Pro camera positioned 7–8 cm
above the preparation. Videos (2 × 20min) of each test condi-
tion were captured and saved in avi format using VirtualDub
software (version 1.9.11).
Colonic migrating motor complexes (CMMCs) were de-
ﬁned as propagating contractions directed from the proximal
to the distal end of the colon, which travelled more than 50%
of the colon length (Roberts et al., 2007; Roberts et al., 2008).
Contractions that propagated less than 50% of the length of
the colon were considered to be short contractions. Another
form of incomplete contraction was identiﬁed as fragmented
contractions occurring simultaneously at different parts of
the colon rather than propagating over the length of the co-
lon. Recordings were used to construct spatiotemporal maps
using in-house edge detection software (Gwynne et al.,
2004). Spatiotemporal maps plot the diameter of the colon
at all points during the recording allowing contractile motor
patterns to be analysed with Matlab software (version 12).
Faecal water content and colonic faecal content
Wet weight of faecal pellets was measured immediately upon
pellet expulsion. Pellets were then dehydrated for 72 h at
room temperature prior to measurement of the dry weight.
Water content was calculated as the difference between the
wet weight and dry weight. Total number of faecal pellets
along the entire length of the colon was counted in freshly
excised intact colons from day 14 sham and oxaliplatin-
treated mice.
Data and statistical analysis
The data and statistical analysis comply with the recommen-
dations on experimental design and analysis in pharmacol-
ogy (Curtis et al., 2015). Data are presented as mean  SEM.
Sample size was calculated based on our previous studies on
the enteric neuropathy and intestinal dysmotility associated
with chemotherapy (Wafai et al., 2013; McQuade et al.,
2016). To detect a 30% change at a power 0.8 and α = 0.05
with 10% SD, the effect size should be minimum n = 5 ani-
mals per group as calculated by the GPOWER program. Data
were assessed using two-way ANOVA, Welch’s two-tailed t-
test and Student’s two-tailed t-test. Analyses were performed
using Graph Pad Prism (Graph Pad Software Inc., CA, USA).
Differences between group means were considered statisti-
cally signiﬁcant at P < 0.05.
Materials
MRS2500 [(1R,2S,4S,5S)-4-[2-iodo-6-(methylamino)purin-9-
yl]-2-phosphonooxy-1-bicyclo [3.1.0]hexanyl]methyl dihy-
drogen phosphate ) was from Tocris, UK; atropine, carbachol,
Nω-nitro-L-arginine (L-NNA), nicardipine and SNP were all
from Sigma-Aldrich, Australia. These compounds were pre-
pared as stock solutions and diluted in physiological saline
daily before addition to preparations.
Results
Loss of enteric neurons and increase in
subpopulations of nNOS-immunoreactive
neurons following oxaliplatin treatment
To investigate changes to the total number of myenteric neu-
rons, whole-mount preparations of the distal and proximal
colonwere labelled with β-tubulin antibody to count neurons
within a 2 mm2 area (Figure 1). Repeated in vivo administra-
tion of oxaliplatin caused myenteric neuronal loss in both
the proximal and distal colon when compared to sham
(Figure 2A). Signiﬁcant neuronal loss was also observed in
the submucosal plexus in the distal colon from oxaliplatin-
treated mice, compared to sham (Figure 2AI).
To determine if oxaliplatin administration was associated
with changes in subpopulations of myenteric neurons, inhib-
itory muscle motor and interneurons IR for nNOS were
analysed. Fewer nNOS-IR neurons were observed in the
myenteric plexus of the both the proximal and distal colon
following oxaliplatin administration when compared with
sham (Figure 2B), but not in the submucosal plexus. The
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proportion of nNOS-IR neurons was, however, signiﬁcantly
increased in the myenteric and submucosal plexus of the
distal colon, but not the myenteric plexus of the proximal
colon from oxaliplatin-treated mice, when compared to
sham-treated mice (Figure 2C,CI).
Reactive oxygen species, iNOS expression and
protein nitration in the submucosal and
myenteric ganglia of the colon following in vivo
oxaliplatin treatment
To evaluate production of ROS following long-term
oxaliplatin treatment, distal colon samples were probed with
a ﬂuorescent mitochondrial superoxide marker MitoSOX™
Red M36008. Increased MitoSOX ﬂuorescence was found in
both the submucosal (Figure 3A,AI and B,BI) and myenteric
(Figure 3C,CI and D,DI) plexuses of the distal colon from
oxaliplatin-treated mice compared to sham-treated animals
(Figure 3E).
Western blot analysis revealed a 40% increase in the ex-
pression of iNOS in LMMP preparations from the colon of
oxaliplatin-treated mice (n = 5 mice/group, Figure 3F).
An antibody against nitrotyrosine was used to label
nitrated proteins within the submucosal (Figure 4A–AII
and B–BII) and myenteric (Figure 4C–CII and D–DII) plex-
uses. The number of neurons per 2 mm2 displaying trans-
location of nitrated proteins to the nuclei was higher in
both the submucosal and myenteric plexuses of the colon
from oxaliplatin-treated ,compared with sham-treated
(Figure 4E).
Apoptosis of submucosal and myenteric
neurons in the colon
Diffusion of cytochrome c out of the mitochondria as a result
of mitochondrial membrane depolarisation and increased
permeability was measured via ﬂuorescence (green) of mono-
meric JC-10. Increased monomeric JC-10 ﬂuorescence was
Figure 1
Whole-mount preparations of myenteric neurons in the proximal and distal colon following 14 days of in vivo oxaliplatin treatment. Myenteric
neurons labelled with anti-β-tubulin III antibody (Tub III, red) counterstained with DAPI (blue) that labels neuronal nuclei within the ganglion (ar-
row) and smooth muscle cell nuclei outside the ganglion (arrowhead) (CI). nNOS-IR neurons (green). Scale bar = 20 μm.
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found in both submucosal (Figure 5A,AI and B,BI) and
myenteric (Figure 5C,CI and D,DI) plexuses of the distal colon
from oxaliplatin-treated mice compared with sham-treated
animals (Figure 5E). Both tissues from both sham and
oxaliplatin-treated mice experienced the same dissection
and therefore the same level of cellular stress associated with
dissection. Cellular stress associated with dissection can in-
duce short-term mitochondrial depolarisation, resulting in
modest increases in JC-10 ﬂuorescence in tissues from both
sham and oxaliplatin-treated mice. However, the level of JC-
10 ﬂuoresce in tissue from oxaliplatin-treated mice was
signiﬁcantly higher (Figure 5) due to long-term mitochon-
drial depolarisation associated with neurotoxicity.
Caspase-3 immunoreactivity was absent in both the sub-
mucosal and myenteric ganglia in the colon preparations
from sham-treated mice, but was observed in both the sub-
mucosal and myenteric ganglia in the colon preparations
from oxaliplatin-treated mice indicating neuronal apoptosis
(not shown, n = 6 mice/group). Caspase-3 labelling appeared
both within the neuronal cell body as well as smaller, irregu-
lar patches of apoptotic debris that did not colocalise with
β-tubulin III immunoreactivity.
Figure 2
Effect of in vivo oxaliplatin treatment on total number of neurons and average number and proportion of nNOS-IR enteric neurons. Average num-
ber of myenteric neurons in the proximal and distal colon and submucosal neurons was counted per 2 mm2 in the distal colon from day 14 sham
and oxaliplatin-treated mice (A,AI). Average number of nNOS-IR neurons (B,BI) in myenteric and submucosal ganglia counted within 2 mm2 area.
Proportion of nNOS-IR neurons to the total number of myenteric and submucosal neurons (C,CI). Data presented as mean  SEM. *P < 0.05, sig-
niﬁcantly different as indicated; n = 6 mice per group per time point.
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Effects of oxaliplatin treatment on
neuromuscular transmission in the colon
Neuromuscular transmission in the distal colon was investi-
gated using intracellular electrophysiology. Electrical stimu-
lation of nerve ﬁbres innervating the circular muscle in
distal colon segments evoked junction potentials in single
smooth muscle cells that were deﬁned as fast inhibitory junc-
tion potentials (fIJPs), slow inhibitory junction potentials
(sIJPs) and excitatory junction potentials (EJPs) using phar-
macological blockers.
In control physiological saline, the restingmembrane poten-
tial (RMP) of smooth muscle cells from sham-treated mice aver-
aged 38  1.0 mV (n = 6 mice) and did not differ from that of
smoothmusclecells fromoxaliplatin-treatedmice(391.0mV,
n = 6mice). RMPs in both groupswere unaffected by the selective
P2Y1 receptor antagonistMRS2500 (1 μM) (sham:39 1.4mV,
oxaliplatin:371.3mV),L-NNA(1mM) (sham:391.3mV,
oxaliplatin: 38  0.9 mV) or the muscarinic antagonist,
atropine(1μM)(sham:381.4mV,oxaliplatin:413.3mV).
The input resistance of smooth muscle cells from sham-treated
mice averaged 8.3 0.9MΩ (n = 6mice) in control physiological
saline; this did not differ signiﬁcantly from the input resistance
of smooth muscle cells from oxaliplatin-treated mice
(8.7  1.0 MΩ, n = 6 mice).
Single pulse and compound stimuli (trains of 20 V,
40 ms interval, 0.4 ms pulse duration) evoked fIJPs in co-
lonic smooth muscle cells (Figure 6A, AI). The amplitudes
of fIJPs recorded in smooth muscle cells from the distal co-
lon of sham-treated mice following a 20 V compound stim-
ulus did not differ signiﬁcantly from those recorded from
the distal colon of oxaliplatin-treated mice (Figure 6B).
The duration of fIJPs (width at half amplitude) was not dif-
ferent between (sham: 397  17 ms) and oxaliplatin-
treated (422  27 ms) groups. The amplitudes of fIJPs
increased with increasing stimulus strength, but no signiﬁ-
cant differences were found in responses between sham
Figure 3
Mitochondrial superoxide in the colonic submucosal and myenteric ganglia and iNOS protein expression. Fluorescent and binary images of
wholemount preparations of submucosal (A,AI and B,BI) and myenteric (C,CI and D,DI) ganglia labelled with MitoSOX™ Red in the colons from
day 14 sham and oxaliplatin-treated mice. Scale bar = 50 μm. (E) Quantiﬁcation of the levels of mitochondrial superoxide production visualized
by ﬂuorescent probe in submucosal and myenteric ganglia in colonic preparations from day 14 sham and oxaliplatin-treated animals. *P < 0.05,
signiﬁcantly different as indicated; n = 6 mice per group. (F) Representative images and quantiﬁcation of the Western blot analysis for iNOS in
LMMP tissue from day 14 sham and oxaliplatin-treated mice. iNOS protein was normalized to total protein values obtained from the Coomassie
Blue membrane staining (see Methods section). All values are expressed as a percentage of the values obtained from sham-treated mice. Data pre-
sented as mean  SEM. *P < 0.05, signiﬁcantly different as indicated; n = 5 mice per group.
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and oxaliplatin-treated mice (Figure 6C). Fast IJPs were
inhibited by MRS2500 (1 μM).
Short compound stimuli (trains of 20 V, 3 pulses, 40 ms
interval, 0.4 ms pulse duration) applied in the presence of
MRS2500 evoked sIJPs (Figure 6D), whose amplitudes were
greater in smooth muscle cells from the distal colon of mice
treated with oxaliplatin than from sham-treated mice (Figure 6E).
The sIJPs were abolished by addition of L-NNA (1 mM).
Short compound stimuli (trains of 20 V, 3 pulses, 40 ms
interval, 0.4 ms pulse duration) of nerve ﬁbres in the presence
Figure 4
Translocation of nitrotyrosine to the nuclei of submucosal andmyenteric neurons. Whole-mount preparations of colonic submucosal ganglia from
day 14 sham (A–AII) and oxaliplatin-treated (B–BII) mice and myenteric ganglia from sham (C–CII) and oxaliplatin-treated (D–DII) mice. Scale
bar = 50 μm. Neurons and ganglia were labelled with anti-β-tubulin III antibody (Tub III, red). Nitrotyrosine within the ganglia was labelled with
anti-nitrotyrosine antibody (NT, green). *P < 0.05, signiﬁcantly different as indicated; n = 6 mice per group.
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of both MRS2500 and L-NNA, inhibiting fast and slow IJPs re-
spectively, evoked EJPs (data not shown). EJPs were inhibited
by atropine (1 μM). The EJPs recorded in smooth muscle cells
from the distal colon of sham-treated mice (6  0.4 mV) did
not differ from those of oxaliplatin-treated mice
(6  0.7 mV). Atropine reduced the amplitude of responses
in sham-treated mice from 6  0.4 to 0.8  0.3 mV
(P < 0.05) and from 6  0.7 to 0.8  0.2 mV in oxaliplatin-
treated mice (P < 0.05, n = 6 animals per group).
Effects of oxaliplatin treatment on colonic
smooth muscles
Smooth muscle tone of the distal colon was studied in organ
bath experiments using force transducers. We measured the
force produced by 3 mm wide circular muscle rings. Applica-
tion of SNP (10 μM) to organ baths containing distal colon
segments resulted in a decrease in circular muscle tone, that
is relaxation, in tissues from both sham (Figure 7A) and
oxaliplatin-treated (Figure 7AI) mice. The reduction in ten-
sion produced by SNP was greater in the colon segments from
sham-treated mice than in segments from oxaliplatin-treated
mice (Figure 7B). Thus, the relaxation force in response to
SNP was reduced in colonic circular muscles from
oxaliplatin-treated mice.
The resting colon diameter measured in organ-bath exper-
iments between contractions was larger in preparations from
mice treated with oxaliplatin (2.4  0.1 mm) compared with
sham-treated mice (2.1  0.1 mm) (n = 7 animals per group)
(Figure 7C). Histological analysis of colon sections revealed
thinning of the colonic muscle layer in oxaliplatin-treated
mice when compared with sham (Figure 7D). Quantitative
analysis conﬁrmed that this reduction was statistically signif-
icant (Figure 7DI).
Colonic motility
Colonic motor patterns. Analysis of the total number of
contractions included all types of motor patterns in the colon
Figure 5
Changes in neuronal mitochondrial membrane potential indicative of cytochrome c release in submucosal and myenteric plexuses. Fluorescent
and binary wholemount preparations of submucosal (A,AI and B,BI) and myenteric (C,CI and D,DI) ganglia labelled with JC-10 dye in the colons
from day 14 sham and oxaliplatin-treatedmice. Green ﬂuorescent colour (JCmonomeric form) is due to the JC-10-labelled release of cytochrome c
diffusing out of the mitochondria as a result of mitochondrial depolarisation and increased permeability. Scale bar = 50 μm. (E) Quantiﬁcation of
the levels of monomeric JC-10 production visualized by ﬂuorescent probe in submucosal andmyenteric ganglia in colonic preparations from sham
and oxaliplatin-treated animals. *P < 0.05, signiﬁcantly different as indicated; n = 6 mice per group.
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(CMMCs, short and fragmented contractions) (Figure 8A).
The frequency, speed of propagation and length of
contractions were measured for each speciﬁc type of motor
activity.The total number and rate of rise of contractions
were reduced in the colons from oxaliplatin-treated animals
compared to sham-treated mice (P < 0.05 for both,
Table 1). The addition of L-NNA did not alter the overall
number of contractions in either group (Figure 8B, Table 1).
Further analysis revealed differences in occurrence of
various types of colonic motor patterns in the oxaliplatin-
treated group with a signiﬁcant decrease in the proportion
of CMMCs (P < 0.05, Figure 8C) and increase in the
proportion of fragmented contractions (P < 0.05, Figure 8E).
Application of L-NNA restored the proportion of CMMCs in
oxaliplatin-treated colons to the levels comparable with
sham-treated colons (Figure 8C), but had no signiﬁcant effect
on the proportion of either short or fragmented contractions
(Figure 8D,E).
Figure 6
Intracellular recordings of fast and sIJPs from colonic smooth muscle cells. Single pulse electrical stimulus (40 V, 0.4 ms duration) and high
frequency compound stimulus (20 V, 0.04 ms interval, 0.4 ms duration) evoked fIJPs in smooth muscle cells from day 14 sham (A) and
oxaliplatin-treated (AI) mice (* stimulus artefact). (B) The mean amplitude of fIJPs in response to compound stimuli from smooth muscle cells
of sham and oxaliplatin-treated mice (n = 4 mice/group). (C) Amplitudes of fIJPs to increasing strength of the electrical stimuli (2–60 V) in
smooth muscle cells of sham and oxaliplatin-treated mice. (D) Blocking fIJPs with a selective antagonist of P2Y1 receptors, MRS2500 (1 μM)
revealed sIJPs in smooth muscle cells from both sham and oxaliplatin-treated mice. (E) Comparison of the amplitude of sIJPs in smooth
muscle cells from sham and oxaliplatin-treated mice. Data presented as mean  SEM. *P < 0.05, signiﬁcantly different as indicated;
n = 6 mice per group.
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Colonic migrating motor complexes. In vivo treatment with
oxaliplatin was associated with a lower CMMC frequency
than in sham-treated preparations (P < 0.05). Application of
L-NNA signiﬁcantly increased the frequency of CMMCs in
colons from oxaliplatin-treated (P < 0.05), but not sham-
treated mice (Figure 9A, Table 1). The rate of rise of CMMCs
was comparable between sham-treated and oxaliplatin-
treated mice, but increased CMMC rate of rise following
addition of L-NNA was noted in the colons from sham
(P < 0.05), but not oxaliplatin-treated animals (Figure 9B,
Table 1).
Short contractions. Treatment with oxaliplatin resulted in a
reduced frequency of short contractions in the colon
(Figure 9C, Table 1). L-NNA had no effect on the frequency
of short contractions in either group. The rate of rise of
short contractions was twofold slower in colons from
oxaliplatin-treated mice (Table 1). L-NNA signiﬁcantly
enhanced the propagation speed of short contractions in
the sham (P < 0.05), but not the oxaliplatin-treated group.
The frequency of short anterograde contractions in the
distal region of the colon was signiﬁcantly reduced in
oxaliplatin-treated animals compared with sham-treated
mice (Figure 9E, Table 1). Short contractions initiated in the
distal colon were also found to travel in a retrograde
direction. These retrograde short contractions occurred at a
signiﬁcantly reduced frequency in colons from oxaliplatin-
treated mice compared to sham-treated mice (Figure 9F,
Figure 7
Effects of oxaliplatin treatment on colonic smooth muscles. (A,AI) Smooth muscle relaxation following application of the NO donor, SNP (10 μM)
to the colon from day 14 sham (A) and oxaliplatin-treated (AI) mice. (B) Comparison of the maximum relaxation produced by circular muscles in
response to SNP in colonic preparations from sham and oxaliplatin-treated mice quantiﬁed as an absolute change in the force transduction from
the basal values. *P < 0.05, signiﬁcantly different as indicated; n = 6 mice per group. (C) Resting diameter of the distal colon from sham and
oxaliplatin-treated mice. *P = 0.05, signiﬁcantly different as indicated; n = 7 mice per group. (D) Gross morphological changes in the colon fol-
lowing repeated in vivo oxaliplatin administration. Colonic crypt length was shorter in oxaliplatin-treated mice and muscle thickness was reduced
in comparison to the sham-treated animals. (DI) Statistical analysis of the muscle layer thickness in the colon preparations from sham and
oxaliplatin-treatedmice. Data presented as mean SEM. *P< 0.05, signiﬁcantly different as indicated; n = 6mice per group, 10 sections per prep-
aration from each animal.
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Table 1). L-NNA had no effects on anterograde or retrograde
short distal contractions in either group.
Fragmented contractions. These were deﬁned as incomplete
contractions occurring simultaneously rather than
propagating over the length of the colon (Figure 10A). The
frequency of fragmented contractions was signiﬁcantly
higher in oxaliplatin-treated than in sham-treated mice
(Figure 10B, Table 1). Application of L-NNA did not affect
the frequency of fragmented contractions in either
oxaliplatin-treated or sham-treated mice.
Colonic faecal content
To deﬁne the clinical symptoms resulting from the altered
patterns of colonic motor activity, fresh faecal pellets were
collected from both sham and oxaliplatin-treated mice and
faecal water content was calculated as the difference between
wet and dry pellet weight (Figure 10C,D). The fresh pellets
(wet weight) from oxaliplatin-treated mice weighed signiﬁ-
cantly less than those of sham-treated mice (Figure 10C). Af-
ter dehydration, the dry weight of pellets from sham-treated
mice and from oxaliplatin-treated mice were not different
(Figure 10C). Thus, the water content was signiﬁcantly lower
Figure 8
Total number of contractions and proportion of different types of contractile activity in the colon before and after application of L-NNA. (A) Ex-
amples of spatiotemporal maps generated from digital video recordings of colonic motility from day 14 sham and oxaliplatin-treated mice before
(control) and after addition of L-NNA. Each contraction can be seen as a reduction in the gut width (red), while relaxation as an increase in the gut
width (blue). CMMCs propagate >50% of the colon length, short contractions (SCs) propagate <50% of the colon length and fragmented con-
tractions (FCs) are interrupted by period(s) of relaxation during contraction. (B) The total number of contractions including all types of contractile
activity in the colons from sham and oxaliplatin-treated mice. The proportion of CMMCs (C), short contractions (D) and fragmented contractions
(E) to the total number of contractions was calculated inmaps from sham-treated and oxaliplatin-treatedmice before and after addition of L-NNA.
Data are presented as an average of contractions per 10min from a total of 40min of video recording at baseline intraluminal pressure prior to and
after the addition of L-NNA. Data presented as mean  SEM. *P < 0.05, signiﬁcantly different as indicated; n = 10 mice per group.
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in pellets collected from oxaliplatin-treated mice than in
those collected from sham-treated mice (Figure 10D). Total
number of pellets within the entire length of excised colons
from oxaliplatin-treated mice was signiﬁcantly higher than
the number in sham-treated mice (Figure 10E).
Discussion
This study is the ﬁrst to examine the role of oxidative stress
in vivo on enteric neurons of the colon that may be involved
in mechanisms underlying colonic dysmotility associated
with oxaliplatin treatment. The results show that mitochon-
drial superoxide and nitrated protein levels are signiﬁcantly
increased in the myenteric and submucosal ganglia after
oxaliplatin treatment. Mitochondrial depolarisation and
increased mitochondrial permeability leading to release of
cytochrome c from mitochondria were increased in
myenteric ganglia in the colon from oxaliplatin-treated mice.
This presumably led to increased expression of an
‘executioner’ caspase-3 in both the submucosal and
myenteric ganglia in the colon preparations from
oxaliplatin-treated mice. Oxidative stress and neuronal apo-
ptosis resulted in functional changes in the colon (increased
nitrergic neuromuscular transmission, decreased smooth
muscle tone, changes in the patterns and parameters of co-
lonic motility) leading to symptoms of constipation in mice
after long-term treatment with oxaliplatin.
Oxaliplatin-induced oxidative stress and
neuronal apoptosis
Oxidative stress in enteric neurons following oxaliplatin
treatment was shown by increased mitochondrial superoxide
and translocation of nitrated proteins in submucosal and
myenteric plexuses as well as the increase in expression of
Table 1
Parameters of different types of colonic contractions
Sham-treated
(n = 10 mice)
Oxaliplatin-treated
(n = 10 mice)
All contractions
Frequency (contractions/10 min) Control 33.8  2.4 21.7  2.9a
L-NNA 31.6  3.9 21.8  3.9
Speed (mm/s) Control 1.8  0.1 1.3  0.2
L-NNA 3.4  0.5 2.1  0.4
CMMCs
Proportion (%) Control 27.8  3.5 9.4  3.7a
L-NNA 32.4  5.9 31.0  6.4b
Frequency (contractions/10 min) Control 9.0  0.9 2.5  1.0a
L-NNA 9.8  2.2 6.0  1.2b
Speed (mm/s) Control 2.2  0.3 2.0  0.5
L-NNA 3.5  0.8a 1.9  0.5
Short contractions
Proportion (%) Control 66.2  2.4 58.5  6.9
L-NNA 55.5  3.9a 42.2  6.2
Frequency (contractions/10 min) Control 22.7  2.4 13.0  2.0a
L-NNA 17.6  2.3 9.8  1.9
Speed (mm·s1) Control 1.6  0.1 0.8  0.1a
L-NNA 2.8  0.6a 1.2  0.2
Distal anterograde short contraction
frequency (per 10 min)
Control 14.5  1.5 6.4  1.5a
L-NNA 10.3  1.5 4.8  1.4
Distal retrograde short contraction
frequency (per 10 min)
Control 2.0  0.6 0.1  0.1a
L-NNA 1.0  0.3 0.3  0.1
Fragmented contractions
Proportion (%) Control 6.0  2.1 32.1  6.1a
L-NNA 12.1  3.1 26.8  5.2
Frequency (contractions/10 min) Control 2.1  0.7 6.2  1.2a
L-NNA 4.2  1.2 6.0  1.1
aP < 0.05 compared with sham-control.
bP < 0.05 compared with oxaliplatin-control.
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iNOS observed in our study. Mitochondria are responsible for
most of the ROS burden under both normal and pathological
conditions. The increased level of mitochondrial superoxide
observed in enteric neurons is consistent with ﬁndings show-
ing increased mitochondrial ROS in neuronal cultures from
dorsal root ganglia of oxaliplatin-treated rats (Kelley et al.,
2014). Inhibition of mitochondrial electron transport chain
complexes I and III involved inmitochondrial ROS formation
improves sensory hyperalgesia in a rat model of peripheral
neuropathy induced by another platinum-based chemother-
apeutic drug, cisplatin (Joseph and Levine, 2009).
Mitotoxicity affecting mitochondrial respiration and ATP
production were found in sciatic nerve from oxaliplatin-
treated rats and linked to oxaliplatin-induced peripheral
neuropathy (Zheng et al., 2011), which could be prevented
by peroxynitrite decomposition catalyst (Janes et al., 2013).
Thus, reduction of oxidative stress-related biomarkers in pe-
ripheral neurons may be a promising avenue for alleviation
of chemotherapy-induced neuropathies.
Oxaliplatin-induced mitochondrial damage has also been
proposed as a potential mechanism leading to activation of
NOS (Areti et al., 2014). The direct toxicity of NO can be
greatly enhanced by reacting with superoxide to form
peroxynitrite, which modiﬁes tyrosines in proteins to create
nitrotyrosines. Nitration of structural proteins can have ma-
jor pathological consequences, but can also be an indicator
of oxidative stress (Beckman and Koppenol, 1996). We iden-
tiﬁed translocation of nitrated proteins in both submucosal
Figure 9
Effects of L-NNA on CMMCs and short contractions. (A) The frequencies of CMMCs quantiﬁed in spatiotemporal maps from sham-treated and
oxaliplatin-treated mice before and after L-NNA application. (B) Speed of CMMCs in the colons from sham and oxaliplatin-treated mice in both
test conditions. *P < 0.05, signiﬁcantly different as indicated; n = 10 mice per group. (C) The frequencies of short contractions were quantiﬁed in
spatiotemporal maps from sham and oxaliplatin-treated mice before and after L-NNA application. (D) Speed of all short contractions analysed
before and after L-NNA application. Changes in the frequency of distal anterograde (E) and retrograde (F) short contractions in the colons from
sham and oxaliplatin-treated mice in both test conditions. Data presented as mean  SEM. *P < 0.05, signiﬁcantly different as indicated; n = 10
mice per group).
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and myenteric plexuses of the colon from oxaliplatin-treated
mice. Translocation of nitrotyrosine has been previously
found in myenteric neurons following ischaemia and reper-
fusion in mice (Rivera et al., 2011b) and induction of colitis
in rats (Zingarelli et al., 2003); both of which were correlated
with increases in NO and ROS. The increased level of iNOS
observed in the LMMP preparations in our study probably
leads to increased production of NO contributing to the ac-
cumulation of nitrotyrosine in enteric neurons. Although
nitration can be used as an indirect measure of
peroxynitrite, accumulation of nitrotyrosine itself is corre-
lated with increased susceptibility to NO-induced apoptosis
(Savidge, 2011). Accumulation of nitrotyrosine has been
linked to protein misfolding, mitochondrial dysfunction
and neuronal degeneration (Nakamura and Lipton, 2008).
Increased ROS and concurrent oxidative stress are linked
to damage in various cellular components, and neuronal
death (Wei et al., 2000).
One of many by-products of oxaliplatin metabolism is ox-
alate and increases in oxalate levels trigger intracellular Ca2+
inﬂux (Webster et al., 2005). Increased cytoplasmic Ca2+ acti-
vates nNOS, potentially leading to excessive NO production
as well as activating the release of cytochrome c (Yagihashi
et al., 2000). Release of JC-10-labelled cytochrome c diffusing
out of the mitochondria as a result of mitochondrial
depolarisation and increased permeability was observed in
Figure 10
Effects of L-NNA on fragmented contractions and colonic faecal content. (A) Fragmented contractions were deﬁned as interrupted contractions
consisting of period(s) of relaxation (arrow) and simultaneously occurring contractions (arrowheads). The frequency (B) of fragmented contrac-
tions in the colon from sham and oxaliplatin-treated mice before and after L-NNA application. (C) Wet weight of faecal pellets measured imme-
diately upon pellet expulsion; dry weight of faecal pellets measured after 72 h of dehydration at room temperature. (D) Faecal water content
calculated as the difference between the wet weight and dry weight. (E) Total number of faecal pellets along the entire length of the colon
counted in freshly excised intact colons. Data presented as mean  SEM. *P < 0.05, signiﬁcantly different as indicated; n = 10 mice per group.
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both submucosal and myenteric neurons in our study. The
increase in superoxide and NO production may be a direct
consequence of the loss of mitochondrial cytochrome c
(Düssmann et al., 2003). The rate of superoxide production
is linked to the magnitude of mitochondrial membrane po-
tential and mitochondrial permeability (Brand et al., 2004).
The magnitude of mitochondrial depolarisation dictates cy-
tochrome c release and hence the activation of apoptosis.
Modest mitochondrial depolarisation is transient and revers-
ible, and has been found to be protective against moderate
tissue injury (Schweizer and Richter, 1994; Gottlieb et al.,
2003). Apoptotic cells exhibit distinctive biochemical fea-
tures, including the presence of speciﬁc cleaved proteins
(Hengartner, 2000). Caspase-3 is a key effector or ‘execu-
tioner’ caspase, cleaving various substrates to cause the mor-
phological and biochemical changes seen in apoptotic cells
(Slee et al., 2001; Elmore, 2007; McIlwain et al., 2013). Our re-
sults are consistent with previous studies using caspase-3 an-
tibody, which found both intracellular immunoreactivity and
detected extracellular aggregates of apoptotic debris outside
neuronal cells (Pasinelli et al., 2000). Due to the fact that
the half-life of activated caspase-3 is 8 h, it is difﬁcult to de-
tect signiﬁcant amounts of activated caspase 3 within en-
teric ganglia. It is possible that the activation of caspase-3
might have occurred at the earlier stages of oxaliplatin
treatment resulting into neuronal apoptosis; this would ex-
plain both neuronal loss and presence of apoptotic debris
observed in our study at day 14. Increased expression of
caspase-3 observed in our study is indicative of
oxaliplatin-induced apoptosis which resulted in 43% loss
of myenteric neurons in the distal colon, 16% of myenteric
neurons in the proximal colon and 30% of submucosal
neurons in the distal colon. Similarly, oxaliplatin treatment
induced 12% loss of myenteric and 21% submucosal neu-
rons in the mouse ileum at day 14 (Robinson et al., 2016).
Although oxaliplatin causes neuronal death in all studied
intestinal regions, it seems that neurons in the distal colon
are more susceptible to oxaliplatin-induced damage than
neurons in the proximal colon and ileum. There may be
many reasons for these regional differences, but it should
be noted that the proportion of the nNOS-IR neurons was
signiﬁcantly increased in the distal, but not proximal colon,
consistent with a role for NO in oxaliplatin-induced enteric
neuronal loss. Moreover, repeated in vivo oxaliplatin admin-
istration induces decreases in glial ﬁbrillary acidic protein-
IR enteric glia, contrasting with increases in s100β-IR
enteric glial cells in both the myenteric and submucosal
ganglia at day 14 after commencement of treatment
(Robinson et al., 2016).
Changes in neuromuscular transmission and
smooth muscle tone
NO released from nNOS expressing inhibitory motor neurons
supplying the intestinal smooth muscles is an integral
inhibitory neurotransmitter in the gastrointestinal tract
(Lecci et al., 2002; Takahashi, 2003). nNOS produces basal
levels of NO tomaintain the hyperpolarised state of the circu-
lar muscle cells leading to physiological tonic inhibition of
the intestine ( Daniel et al., 1994). Excessive NO production
and consequent nitrosylation has been linked to inhibition
of dynamin-related protein 1, resulting in synaptic impair-
ment and disruption to synaptic transmission (Savidge,
2011). In our study, intracellular recordings from colonic cir-
cular muscles revealed changes in neuromuscular transmis-
sion with an increase in amplitude of NO-mediated sIJPs
potentials in the oxaliplatin-treated group. No changes in
ATP-mediated fIJPs or ACh-mediated EJPS were observed.
These results differ from ﬁndings in inﬂamed guinea pig
colon where oxidative stress leads to reduced purinergic neu-
romuscular transmission (Roberts et al., 2013). This may be
due to differences in mechanisms of oxaliplatin-induced
neuronal damage from inﬂammation-induced enteric neu-
ropathy. Oxaliplatin exerts its cytotoxic effects via direct
binding to nuclear and mitochondrial DNA and formation
of platinum-DNA adducts (Graham et al., 2000; Goodisman
et al., 2006). Direct mitochondrial damage leads to excessive
NO production and activation of apoptotic cascades as
discussed above.
Direct oxaliplatin toxicity and increased NO signalling al-
ter the functions of colonic circular muscles. The relaxation
evoked by the NO donor, SNP, was reduced by about 50% in
the distal colon from oxaliplatin-treated mice. The baseline
diameter of the distal colon was greater in oxaliplatin-treated
animals than in sham-treated mice suggesting a reduction in
the colonic muscle tone after oxaliplatin treatment. This was
reversed by application of L-NNA inhibiting all NOS isoforms
including iNOS, which was increased in longitudinal muscle-
myenteric neuron preparations after oxaliplatin treatment.
The reduced smooth muscle tone as well the reduced re-
sponse to the NO donor could be a result of the relatively
higher inhibitory activity compared with the excitatory due
to the increased proportion of nNOS neurons observed in
oxaliplatin-treated mice. The reduction in muscle thickness
that we observed after oxaliplatin treatment may also
contribute to a reduction in muscle tone. Decreased basal
tone and, thus, a larger resting diameter of the distal colon
compromised the ability of smooth muscles to further relax.
Similar ﬁndings have been observed following intestinal
inﬂammation where smooth muscle relaxation in response
to a NO donor was decreased (Van Bergeijk et al., 1998;
Rajagopal et al., 2015). This compromised ability to relax
was in part attributed to iNOS-mediated protein nitrosylation
(Rajagopal et al., 2015).
Oxaliplatin-induced changes in colonic
motility
To investigate the role of NO in colonic dysmotility resulting
from oxaliplatin treatment, we performed experiments with
and without application of the NOS inhibitor, L-NNA, and
analysed phases of contraction in various parts of the colon,
overall colonic motor patterns and parameters of speciﬁc
types of motor activity.
Alterations in the basal tone of the colon and augmented
nitrergic transmission may be attributed to increased NO re-
lease providing enhanced inhibitory input to the smooth
muscle and altering colonic contractile patterns. Analysis of
spatiotemporal maps revealed reductions in the proportion
and frequency of CMMCs as well as in frequency and speed
of short contractions in the distal colon from oxaliplatin-
treated mice. Anterograde and retrograde short contractions
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were observed in the distal colon of both sham and
oxaliplatin-treated mice. Both types of short contractions
were signiﬁcantly reduced in the distal colon after oxaliplatin
treatment. In contrast, the proportion and frequency of
fragmented contractions were greater in colons from
oxaliplatin-treated mice. These ﬁndings are consistent
with previous studies demonstrating inhibition of CMMCs
in the colon of oxaliplatin-treated mice (Wafai et al., 2013)
and inhibition of intestinal transit in cisplatin-treated rats
(Vera et al., 2011).
Previous studies using NOS inhibitors have established a
role of NO in the pathophysiology of gastrointestinal
functional disorders (Rivera et al., 2011a). NO is a primary reg-
ulator of complex intestinalmotor patterns and increased NO
release can disrupt CMMCs (Sarna et al., 1993; Rodriguez-
Membrilla et al., 1995; Castro et al., 2012). In our study, appli-
cation of the NOS inhibitor, L-NNA, restored the proportion
and frequency of CMMCs in oxaliplatin-treated mice. NOS
inhibition increased the rate of rise of all types of contrac-
tions (CMMCs, short and fragmented) in the colons from
sham-treated, but not oxaliplatin-treated mice. This is consis-
tent with previous studies reporting increased speed of con-
traction induced by L-NNA in control mice (Rodriguez-
Membrilla et al., 1995). Inhibition of NOS by L-NNA did not
affect short and fragmented contractions in colons from
oxaliplatin-treated mice. This suggests that the augmented
proportion and frequency of fragmented contractions and re-
duced frequency of short contractions observed in
oxaliplatin-treated mice are not due to increased NO release,
but can be attributed to either disruption of enteric neural
pathways or a direct effect on colonic smooth muscle func-
tion. Colonic dysmotility was associated with reduction in
faecal water content and increase in number of pellets in
the colon providing evidence that oxaliplatin-treated mice
had constipation.
In conclusion, oxaliplatin treatment induces severe gas-
trointestinal side-effects such as nausea, vomiting, constipa-
tion and diarrhoea, which account for dose limitations
and/or cessation of treatment. These symptoms can persist
up to 10 years after the treatment has been ceased (Denlinger
and Barsevick, 2009). Oxidative stress has been suggested as
a potential mechanism underlying platinum neurotoxicity
(Di Cesare Mannelli et al., 2012). Our study is the ﬁrst provid-
ing evidence that oxidative stress is a key player in enteric
neuronal death, changes in intestinal smooth muscle tone
and neuromuscular transmission underlying colonic
dysmotility and leading to chronic constipation associated
with oxaliplatin treatment. Further studies elucidatingmech-
anisms of oxaliplatin-induced oxidative stress are warranted
in order to develop strategies to alleviate gastrointestinal
side-effects of chemotherapy and achieve more effective
anti-cancer treatment.
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